Objectives and Specific Aims Gammadelta T cells have unique features in comparison to alphabeta T cells. It has now become clear that gammadelta T cells recognize non- peptide and non-processed bacterial and environmental antigens, as well as stress-associated antigens expressed on epithelial cells and on certain tumor lines and primary carcinomas. However, understanding of gammadelta T cell biology has lagged behind that of alphabeta T cells. Recently, I have demonstrated that gammadelta T cells favor the Thl pathway of cytokine polarization, predominantly producing IFN-gamma. Furthermore, I have shown in my follow-up studies that the dominance of T-bet over GATA-3 leads to the default Thl-like pathway in gammadelta T cells. Based on these data, I hypothesize that gammadelat T cells play an important role in tumor immunity through their predominant production of IFN-gamma. To further address this hypothesis, I plan the following specific aims:
Aim 1. To further define the factors that modulate IFN-gamma production by gammadelta T cell in vitro. Here I will further characterize the molecular mechanisms of gammadelta T cell IFN-gamma production, focusing upon the balance between T-bet and GATA-3 in IFN-gamma production.
Aim 2. To define the role of IFN-gamma produced by gammadelta T cells in tumor immunity. Here I will define the role of IFN-gamma secreted solely by gammadelta T cells in a chemically-induced fibroscarcomas model. I will construct mice in which gammadelta T cells selectively lack the capacity to make IFN-gamma. Then I will challenge these mice with chemically-induced tumors.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Center Core Grants (P30)
Project #
5P30AR041942-09
Application #
6577708
Study Section
Special Emphasis Panel (ZAR1)
Project Start
2002-04-01
Project End
2003-03-31
Budget Start
Budget End
Support Year
9
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Yale University
Department
Type
DUNS #
082359691
City
New Haven
State
CT
Country
United States
Zip Code
06520
Dainichi, Teruki; Hayden, Matthew S; Park, Sung-Gyoo et al. (2016) PDK1 Is a Regulator of Epidermal Differentiation that Activates and Organizes Asymmetric Cell Division. Cell Rep 15:1615-23
Askenase, Phillip W; Bryniarski, Krzysztof; Paliwal, Vipin et al. (2015) A subset of AID-dependent B-1a cells initiates hypersensitivity and pneumococcal pneumonia resistance. Ann N Y Acad Sci 1362:200-14
Clark, Paul R; Jensen, Todd J; Kluger, Martin S et al. (2011) MEK5 is activated by shear stress, activates ERK5 and induces KLF4 to modulate TNF responses in human dermal microvascular endothelial cells. Microcirculation 18:102-17
Kwong, Bernice Y; Roberts, Scott J; Silberzahn, Tobias et al. (2010) Molecular analysis of tumor-promoting CD8+ T cells in two-stage cutaneous chemical carcinogenesis. J Invest Dermatol 130:1726-36
Radtke, Christine; Vogt, Peter M; Devor, Marshall et al. (2010) Keratinocytes acting on injured afferents induce extreme neuronal hyperexcitability and chronic pain. Pain 148:94-102
Kirkiles-Smith, Nancy C; Harding, Martha J; Shepherd, Benjamin R et al. (2009) Development of a humanized mouse model to study the role of macrophages in allograft injury. Transplantation 87:189-97
Koga, Yasuo; Pelizzola, Mattia; Cheng, Elaine et al. (2009) Genome-wide screen of promoter methylation identifies novel markers in melanoma. Genome Res 19:1462-70
Yates, Kristin E; Korbel, Gregory A; Shtutman, Michael et al. (2008) Repression of the SUMO-specific protease Senp1 induces p53-dependent premature senescence in normal human fibroblasts. Aging Cell 7:609-21
Pelizzola, Mattia; Koga, Yasuo; Urban, Alexander Eckehart et al. (2008) MEDME: an experimental and analytical methodology for the estimation of DNA methylation levels based on microarray derived MeDIP-enrichment. Genome Res 18:1652-9
Shen, Xiaoyan; Berger, Carole L; Tigelaar, Robert et al. (2008) Development of immunogenic tumor-loaded dendritic cells through physical perturbation and apoptotic cell loading. Immunol Invest 37:798-821

Showing the most recent 10 out of 97 publications